Aemetis Stock Forecast, Price & News

Aemetis (NASDAQ:AMTX) Frequently Asked Questions

Is Aemetis a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aemetis in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Aemetis stock.
View analyst ratings for Aemetis or view top-rated stocks.

How has Aemetis' stock price been impacted by COVID-19?

Aemetis' stock was trading at $0.6511 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AMTX stock has increased by 2,206.9% and is now trading at $15.02.
View which stocks have been most impacted by COVID-19.

When is Aemetis' next earnings date?

Aemetis is scheduled to release its next quarterly earnings announcement on Monday, March 21st 2022.
View our earnings forecast for Aemetis.

How were Aemetis' earnings last quarter?

Aemetis, Inc. (NASDAQ:AMTX) released its earnings results on Thursday, November, 11th. The specialty chemicals company reported ($0.55) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.30) by $0.25. The specialty chemicals company had revenue of $49.90 million for the quarter, compared to analyst estimates of $54.23 million. During the same period in the previous year, the firm earned ($0.59) earnings per share.
View Aemetis' earnings history.

What price target have analysts set for AMTX?

8 Wall Street analysts have issued 12 month price targets for Aemetis' shares. Their forecasts range from $25.00 to $35.00. On average, they anticipate Aemetis' stock price to reach $31.17 in the next year. This suggests a possible upside of 107.5% from the stock's current price.
View analysts' price targets for Aemetis or view top-rated stocks among Wall Street analysts.

Who are Aemetis' key executives?

Aemetis' management team includes the following people:

• Eric Armstrong McAfee, Chairman & Chief Executive Officer
• Todd A. Waltz, Chief Financial Officer, Secretary & Executive VP
• Andrew B. Foster, Executive Vice President (LinkedIn Profile)
• Sanjeev Gupta, President-Aemetis International

Who are some of Aemetis' key competitors?

Some companies that are related to Aemetis include Green Plains (GPRE), Amyris (AMRS), Gevo (GEVO), Origin Materials (ORGN), Westlake Chemical Partners (WLKP), Cyclo Therapeutics (CTDH), REX American Resources (REX), Alto Ingredients (ALTO), FutureFuel (FF), Green Plains Partners (GPP), SolarWindow Technologies (WNDW), TOMI Environmental Solutions (TOMZ), Cyclo Therapeutics (CYTH), Tantech (TANH) and American Energy Partners (AEPT).
View all of AMTX's competitors.

What other stocks do shareholders of Aemetis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aemetis investors own include Pennsylvania Real Estate Investment Trust (PEI), Zosano Pharma (ZSAN), Cannabics Pharmaceuticals (CNBX), Gran Tierra Energy (GTE), Tilly's (TLYS), Auxly Cannabis Group (CBWTF), Novan (NOVN), Aeterna Zentaris (AEZS), American Cannabis (AMMJ) and Bionano Genomics (BNGO).

What is Aemetis' stock symbol?

Aemetis trades on the NASDAQ under the ticker symbol "AMTX."

Who are Aemetis' major shareholders?

Aemetis' stock is owned by a variety of institutional and retail investors. Top institutional investors include Grantham Mayo Van Otterloo & Co. LLC (6.05%), BlackRock Inc. (5.77%), Millennium Management LLC (2.21%), Renaissance Technologies LLC (1.83%), Geode Capital Management LLC (1.45%) and Morgan Stanley (1.27%). Company insiders that own Aemetis stock include Andrew B Foster, Andrew B Foster, Francis P Barton, Francis P Barton, John R Block, John R Block, Sanjeev Gupta, Sanjeev Gupta and Todd Waltz.
View institutional ownership trends for Aemetis.

Which institutional investors are selling Aemetis stock?

AMTX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Morgan Stanley, Caption Management LLC, OLD Mission Capital LLC, Deutsche Bank AG, California State Teachers Retirement System, Wolverine Trading LLC, and Advisor Group Holdings Inc.. Company insiders that have sold Aemetis company stock in the last year include Andrew B Foster, Francis P Barton, John R Block, Sanjeev Gupta, and Todd Waltz.
View insider buying and selling activity for Aemetis or view top insider-selling stocks.

Which institutional investors are buying Aemetis stock?

AMTX stock was purchased by a variety of institutional investors in the last quarter, including Grantham Mayo Van Otterloo & Co. LLC, Schonfeld Strategic Advisors LLC, Millennium Management LLC, Wellington Management Group LLP, Goldman Sachs Group Inc., Balyasny Asset Management LLC, Balyasny Asset Management LLC, and BlackRock Inc..
View insider buying and selling activity for Aemetis or or view top insider-buying stocks.

How do I buy shares of Aemetis?

Shares of AMTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aemetis' stock price today?

One share of AMTX stock can currently be purchased for approximately $15.02.

How much money does Aemetis make?

Aemetis has a market capitalization of $499.42 million and generates $165.56 million in revenue each year. The specialty chemicals company earns $-36.66 million in net income (profit) each year or ($2.26) on an earnings per share basis.

How many employees does Aemetis have?

Aemetis employs 164 workers across the globe.

What is Aemetis' official website?

The official website for Aemetis is www.aemetis.com.

Where are Aemetis' headquarters?

Aemetis is headquartered at 20400 STEVENS CREEK BLVD SUITE 700, CUPERTINO CA, 95014.

How can I contact Aemetis?

Aemetis' mailing address is 20400 STEVENS CREEK BLVD SUITE 700, CUPERTINO CA, 95014. The specialty chemicals company can be reached via phone at (408) 213-0940, via email at [email protected], or via fax at 408-252-8044.